3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
8
Head & Neck
1
Gynecologic
1
Conditions
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
2
Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Low Grade Serous Ovarian Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Granulosa Cell Ovarian Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Stromal Tumors
1
Carcinoma
1
Breast Diseases
1
Interventions
Fulvestrant
3
ribociclib
1
palbociclib
1
exemestane
1
abemaciclib
1
Tamoxifen
1
STX-478
1
Metformin
1
Letrozole
1
Imlunestrant
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Diseases
×
Anastrozole
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled